Compounds and methods for kinase modulation, and indications therefor
US-2017319559-A1 · Nov 9, 2017 · US
NAT10 modulators for treating or preventing laminopathies, aging and cancer
US9809562B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9809562-B2 |
| Application number | US-201515301485-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 2, 2015 |
| Priority date | Apr 3, 2014 |
| Publication date | Nov 7, 2017 |
| Grant date | Nov 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterized by low levels of LMNA expression).
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound selected from: and salts or solvates of any one thereof. 2. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 3. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 4. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 5. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 6. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 7. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 8. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 9. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 10. A compound according to claim 1 , wherein the compound is or a salt or solvate thereof. 11. A pharmaceutical composition comprising a compound according to claim 1 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 12. A pharmaceutical composition comprising a compound according to claim 2 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 13. A pharmaceutical composition comprising a compound according to claim 3 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 14. A pharmaceutical composition comprising a compound according to claim 4 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 15. A pharmaceutical composition comprising a compound according to claim 5 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 16. A pharmaceutical composition comprising a compound according to claim 6 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 17. A pharmaceutical composition comprising a compound according to claim 7 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 18. A pharmaceutical composition comprising a compound according to claim 8 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 19. A pharmaceutical composition comprising a compound according to claim 9 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s). 20. A pharmaceutical composition comprising a compound according to claim 10 and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).
Assignees
Inventors
Classifications
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
Free radical scavengers or antioxidants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9809562B2 cover?
- The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer (such as a cancer characterized by low levels of LMNA expression).
- Who is the assignee on this patent?
- Cambridge Entpr Ltd, The Centre Nat De La Rech Scient
- What technology area does this patent fall under?
- Primary CPC classification C07D285/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).